Tarsus Pharmaceuticals Reports Q3 XDEMVY Sales Surge to $119 Million
Tarsus Pharmaceuticals Inc. reported a significant increase in Q3 2025 financial results, with XDEMVY® net sales reaching $119 million, a 147% year-over-year rise. Year-to-date sales totaled $299.7 million, driven by 266,000 bottles delivered. The company also saw a 30% increase in weekly prescribers. As of September 30, 2025, Tarsus had $401.8 million in cash and equivalents. Cost of sales rose to $19.8 million due to higher manufacturing costs. The company plans to expand its pipeline targeting ocular rosacea.
Tarsus Pharmaceuticals Inc. reported strong financial results for the third quarter of 2025, with XDEMVY® net sales reaching approximately $119 million, a 147% increase year-over-year. Year-to-date product sales totaled $299.7 million, up from $113.7 million during the same period in 2024, driven by approximately 266,000 bottles of XDEMVY delivered to patients, compared to 104,400 bottles the previous year. The company also noted a 30% increase in weekly multi-patient prescribers during the third quarter. As of September 30, 2025, Tarsus held $401.8 million in cash, cash equivalents, and marketable securities. Cost of sales rose to $19.8 million from $7.9 million in 2024, reflecting increased manufacturing costs and royalty payments. The company highlighted continued commercial momentum and plans to expand its pipeline with new programs targeting conditions such as ocular rosacea. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568556-en) on November 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
